Truist reiterates Eli Lilly stock rating on obesity drug approval

FDA approval of Eli Lilly's oral obesity drug Foundayo is the headline event, with Truist reiterating a Buy and $1,281 price target. Truist models $1.2B in 2026 sales (vs $1.5B consensus) and peak U.S. sales of $26B in 2036 (consensus $14B); Lilly reported 45% revenue growth over the last 12 months and a market cap of ~$872B. Foundayo pricing: $25/month with commercial insurance, $149/month self-pay, and expected Medicare coverage at $50/month from July 1, 2026; product will be sold as tablets. Lilly also announced acquisition of Centessa for roughly $7.8B (including CVRs) and received positive analyst reiterations from Barclays and BMO, reinforcing a favorable near- to mid-term outlook for the stock.

Analysis

The move to an oral, tablet-first obesity franchise changes the supply-side economics: tablets compress COGS and shorten ramp timelines versus complex injectables, shifting bargaining power toward internal manufacturing and large CMOs that can scale tablet production quickly. That will create winners among API providers and specialty tableting CMOs while pressuring margins for outfits dependent on injectable fill/finish capacity; expect a 6–18 month window where capacity reallocation creates pricing dislocations for contract manufacturers.

On the demand/payer side, an affordable oral option will act as a price anchor that accelerates formulary negotiations and broadens patient uptake, but it also concentrates downside risk on reimbursement decisions and safety surveillance. Key catalysts are payer coverage expansion, CMO ramp rates, and any post-launch adverse-event signals — each can swing realized sales by ±30% over 12–24 months and compress implied peak valuations if negative.

The market appears to be front-running a multi-decade monopoly outcome; second-order risks include faster-than-expected competitive entry (oral and injectable), PBM countermeasures, and regulatory attention to population-level prescribing. That argues for a barbell approach: own the scale/quality leader while hedging with event-driven or short-dated protection and trimming momentum tech exposure that will face rotation into healthcare near-term.

Key Decisions for Investors

• Long LLY (equity or 12–18 month calls): enter on mild pullback (<3%) or scale in over 6 weeks. Target +20–30% upside in 12 months; hard stop -10%. Rationale: margin leverage from tablet manufacturing and faster uptake vs peers; hedge with 2–3% portfolio allocation of short-dated puts to protect downside.
• Relative trade — Long LLY / Short NVO (ratio 1:0.6), 9–15 month horizon: target 15–25% relative outperformance if oral adoption shifts share dynamics. Cut losses if the pair moves against you by 10% absolute or if major payer signals favor injectables.
• Event-arb on CNTA exposure: if deal-related spread exists, size as an arbitrage (small position, 3–5% NAV) with a target capture of 6–12% over 1–6 months; pair with short biotech basket to limit idiosyncratic risk. Exit if regulatory/financing conditions change or spread widens beyond historical deal-arb thresholds.
• Rebalance tech/momentum holdings (SMCI, APP): trim 25–40% of exposure and redeploy into healthcare winners (LLY, selective CDMOs). Timeframe: reallocation over next 2–4 weeks to capture rotation risk; expect lower volatility and ~1.5:1 risk/reward versus holding momentum into the healthcare news cycle.